NCT05607108

A Study of ZEN003694 in People With Squamous Cell Lung Cancer

Phase 2 Trial of ZEN003694 in Squamous Cell Lung Cancer Patients Harboring NSD3 Amplification

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 13 (estimated)
• Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to find out whether ZEN003694 is an effective treatment for people with advanced squamous cell lung cancer with a mutation in the NSD3 gene. ZEN003694 is a type of drug called a BET inhibitor. Researchers think ZEN003694 may help here because the drug works by blocking a group of proteins called bromodomain and extra-terminal (BET) proteins, which may counteract the effect of NSD3 on tumor growth. Blocking these proteins may slow or stop the growth of the cancer.

Conditions

• Squamous Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	ZEN003694	ZEN003694 60mg po qd on a 5 days on 2 days off schedule in an every 21-day cycle

Timeline

• Start date: 2022-11-01
• Primary completion: 2027-11-01
• Completion: 2027-11-01
• First posted: 2022-11-07
• Last updated: 2026-03-11

Locations

7 sites across 1 country: United States

Regulatory

• FDA-regulated drug study